__NUXT_JSONP__("/drugs/Utomilumab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1417318-27-4",chebiId:b,chemicalFormula:b,definition:"A human, agonistic immunoglobulin (Ig) G2 monoclonal antibody (mAb) targeting 4-1BB (CD137, TNFRSF9), with potential immunostimulating activity. Upon administration, utomilumab binds to and activates 4-1BB expressed on various immune cells, such as CD8-positive and CD4-positive T cells and natural killer (NK) cells. This enhances 4-1BB-mediated signaling, induces cytokine production and promotes anti-tumor immune responses. 4-1BB, a member of the tumor necrosis factor (TNF)\u002Fnerve growth factor (NGF) family of receptors, plays an important role in the regulation of immune responses.",fdaUniiCode:"6YY8O697VF",identifier:"C116619",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C155745"],synonyms:["PF 05082566","PF 5082566","PF-05082566","PF-2566","UTOMILUMAB",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FUtomilumab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Utomilumab","","2021-10-30T13:19:08.983Z")));